EVO
Evotec SE ADR
NASDAQ: EVO · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$3.11
+5.78% today
Updated 2026-04-30
Market cap
$1.04B
P/E ratio
—
P/S ratio
1.33x
EPS (TTM)
$-0.34
Dividend yield
—
52W range
$2 – $5
Volume
0.1M
Evotec SE ADR (EVO) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$3.11
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.6B | $0.8B | $0.8B | $0.8B | $0.8B | $0.8B | $0.9B | $1.0B | $1.1B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 8.62% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -13.10%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.